Merck to Buy Idenix for $3.9B for Hepatitis C Drugs

June 9 (Bloomberg) -- Merck & Co. agreed to buy Idenix Pharmaceuticals Inc. for about $3.85 billion to add experimental drugs to treat hepatitis C. Adam Johnson reports on Bloomberg Television’s “Bloomberg Surveillance.” (Source: Bloomberg)

Full Show: What'd You Miss? (02/17)
53:34 - Full episode of "What'd You Miss?" Guests include: Bloomberg's Michelle Jamrisko, Joe Ciolli, Kevin Cirilli and Mark Cudmore. (Source: Bloomberg)
  • Full Show: Bloomberg Best (02/17)
  • Korean Conglomerates Take Hit in Wake of Samsung Scandal
  • Wizards Owner Leonsis on Sports Gambling, Expansion Teams